Success Metrics

Clinical Success Rate
90.0%

Based on 45 completed trials

Completion Rate
90%(45/50)
Active Trials
7(10%)
Results Posted
40%(18 trials)
Terminated
5(7%)

Phase Distribution

Ph not_applicable
3
4%
Ph phase_4
15
21%
Ph phase_1
19
27%
Ph phase_2
11
15%
Ph phase_3
14
20%

Phase Distribution

19

Early Stage

11

Mid Stage

29

Late Stage

Phase Distribution62 total trials
Phase 1Safety & dosage
19(30.6%)
Phase 2Efficacy & side effects
11(17.7%)
Phase 3Large-scale testing
14(22.6%)
Phase 4Post-market surveillance
15(24.2%)
N/ANon-phased studies
3(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.9%

45 of 53 finished

Non-Completion Rate

15.1%

8 ended early

Currently Active

7

trials recruiting

Total Trials

71

all time

Status Distribution
Active(10)
Completed(45)
Terminated(8)
Other(8)

Detailed Status

Completed45
unknown8
Terminated5
Recruiting4
Active, not recruiting3
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
71
Active
7
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 119 (30.6%)
Phase 211 (17.7%)
Phase 314 (22.6%)
Phase 415 (24.2%)
N/A3 (4.8%)

Trials by Status

active_not_recruiting34%
not_yet_recruiting34%
terminated57%
recruiting46%
unknown811%
completed4563%
withdrawn34%

Recent Activity

Clinical Trials (71)

Showing 20 of 71 trialsScroll for more
NCT07532304Phase 1

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

Not Yet Recruiting
NCT05652478Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Recruiting
NCT05630638Phase 4

Doravirine Dose Optimisation in Pregnancy

Recruiting
NCT07124559Phase 1

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

Not Yet Recruiting
NCT05122767Phase 1

Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)

Active Not Recruiting
NCT05979311Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active Not Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT04771754Phase 1

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Completed
NCT03194165

Population Pharmacokinetics of Antiretroviral in Children

Completed
NCT06805656Phase 2

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not Yet Recruiting
NCT02259127Phase 2

ODYSSEY (PENTA 20)

Completed
NCT02656511Phase 4

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

Active Not Recruiting
NCT03249181Phase 3

Dolutegravir in Pregnant HIV Mothers and Their Neonates

Completed
NCT04862975

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

Completed
NCT02987530Phase 3

National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection

Completed
NCT06281834Phase 1

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Recruiting
NCT04166474Phase 4

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

Completed
NCT04493216Phase 2

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Terminated
NCT04805944

Gut Microbiota, PGx and INSTIs Response

Completed
NCT02437110Phase 1

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
71